Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Oppenheimer 25th Annual Healthcare Life Sciences Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Oppenheimer 25th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for February 11, 2025, at 2:40 p.m. ET.
The presentation will be accessible via webcast through the Investors section of Voyager's website at ir.voyagertherapeutics.com. Interested parties can access a replay of the webcast, which will remain available on the company's website for a minimum of 30 days following the presentation.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was -1.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025.
A webcast of the presentation will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company’s website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Mike Hencke, mhencke@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.